Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACON NYSE:ATIP NASDAQ:BMGL NASDAQ:MGRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACONAclarion$3.28+4.1%$3.29$2.34▼$12.03$8.07M1.18564,330 shs133,723 shsATIPATI Physical Therapy$0.68$0.77$0.36▼$1.04$2.98M-0.153,676 shs10 shsBMGLBasel Medical Group$0.59+1.6%$0.63$0.49▼$9.40$11.16M0.0732,053 shs16,961 shsMGRXMangoceuticals$0.43-11.0%$0.39$0.16▼$2.75$7.38M2.127.88 million shs430,376 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACONAclarion+0.96%-3.37%-6.53%+14.96%-54.28%ATIPATI Physical Therapy0.00%0.00%0.00%0.00%-18.67%BMGLBasel Medical Group+5.78%+1.61%+0.65%+3.95%-38.82%MGRXMangoceuticals-2.56%+10.27%+34.13%-9.72%-77.11%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACONAclarion$3.28+4.1%$3.29$2.34▼$12.03$8.07M1.18564,330 shs133,723 shsATIPATI Physical Therapy$0.68$0.77$0.36▼$1.04$2.98M-0.153,676 shs10 shsBMGLBasel Medical Group$0.59+1.6%$0.63$0.49▼$9.40$11.16M0.0732,053 shs16,961 shsMGRXMangoceuticals$0.43-11.0%$0.39$0.16▼$2.75$7.38M2.127.88 million shs430,376 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACONAclarion+0.96%-3.37%-6.53%+14.96%-54.28%ATIPATI Physical Therapy0.00%0.00%0.00%0.00%-18.67%BMGLBasel Medical Group+5.78%+1.61%+0.65%+3.95%-38.82%MGRXMangoceuticals-2.56%+10.27%+34.13%-9.72%-77.11%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACONAclarion 2.00Hold$7.50128.66% UpsideATIPATI Physical Therapy 0.00N/AN/AN/ABMGLBasel Medical Group 1.00SellN/AN/AMGRXMangoceuticals 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest ATIP, BMGL, MGRX, and ACON Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2026ACONAclarion Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$7.00 ➝ $7.505/22/2026ACONAclarion Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)5/8/2026ACONAclarion Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)5/8/2026BMGLBasel Medical Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/24/2026ACONAclarion Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)4/24/2026BMGLBasel Medical Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)3/27/2026MGRXMangoceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 5/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACONAclarion$80K100.86N/AN/A$7.98 per share0.41ATIPATI Physical Therapy$741.86M0.00$3.55 per share0.19($23.96) per share-0.03BMGLBasel Medical Group$8.90M1.25N/AN/A$0.20 per share2.97MGRXMangoceuticals$460K16.05N/AN/A$0.78 per share0.55Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACONAclarion-$7.23M-$9.03N/AN/AN/A-10,320.51%-54.41%-51.71%8/13/2026 (Estimated)ATIPATI Physical Therapy-$69.79M-$19.42N/AN/AN/A-7.79%N/A-3.87%N/ABMGLBasel Medical Group-$9.50MN/AN/AN/AN/AN/AN/AN/AN/AMGRXMangoceuticals-$20.64M-$1.49N/AN/AN/A-4,639.13%-112.00%-104.96%N/ALatest ATIP, BMGL, MGRX, and ACON EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/19/2026Q1 2026MGRXMangoceuticalsN/A-$0.22N/A-$0.22N/A$0.07 million5/13/2026Q1 2026ACONAclarion-$1.55-$1.34+$0.21-$1.34$0.03 million$0.02 million3/18/2026Q4 2025ACONAclarion-$3.60-$2.01+$1.59-$2.01$0.02 million$0.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACONAclarionN/AN/AN/AN/AN/AATIPATI Physical TherapyN/AN/AN/AN/AN/ABMGLBasel Medical GroupN/AN/AN/AN/AN/AMGRXMangoceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACONAclarionN/A19.6519.65ATIPATI Physical TherapyN/A1.121.12BMGLBasel Medical GroupN/AN/AN/AMGRXMangoceuticalsN/A0.290.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACONAclarion7.52%ATIPATI Physical Therapy72.60%BMGLBasel Medical GroupN/AMGRXMangoceuticals56.72%Insider OwnershipCompanyInsider OwnershipACONAclarion0.77%ATIPATI Physical Therapy3.30%BMGLBasel Medical GroupN/AMGRXMangoceuticals16.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACONAclarion72.46 million2.44 millionNot OptionableATIPATI Physical Therapy5,6004.41 million4.27 millionNo DataBMGLBasel Medical Group3618.79 millionN/AN/AMGRXMangoceuticals317.17 million14.42 millionNot OptionableATIP, BMGL, MGRX, and ACON HeadlinesRecent News About These CompaniesMangoceuticals Inc.May 18, 2026 | marketwatch.comHead-To-Head Review: Mangoceuticals (NASDAQ:MGRX) versus Karyopharm Therapeutics (NASDAQ:KPTI)May 18, 2026 | americanbankingnews.comMangoceuticals Delays Quarterly Filing After Audit ReviewMay 15, 2026 | tipranks.comMangoceuticals Insider Trading Activity | NASDAQ:MGRX | BenzingaApril 13, 2026 | benzinga.comMangoceuticals Delays Annual 10-K Yearly FilingMarch 31, 2026 | tipranks.comMangoceuticals, Inc.: Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity ...March 23, 2026 | finanznachrichten.deMangoceuticals (MGRX) Stock Rockets 130% Following CEO’s Substantial Share AwardMarch 23, 2026 | blockonomi.comWhy Is Mangoceuticals, Inc. Stock (MGRX) Up Today?March 23, 2026 | tipranks.comMangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc.March 17, 2026 | globenewswire.comMangoceuticals, Inc. Files International Patent Application for Innovative Antiviral Feed Additive Technology MGX-0024March 6, 2026 | quiverquant.comQMangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or BirdsMarch 6, 2026 | markets.businessinsider.comMangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or BirdsMarch 6, 2026 | globenewswire.comMangoceuticals’ Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled ...February 23, 2026 | markets.businessinsider.comMangoceuticals Highlights Promising MGX-0024 Poultry Antiviral DataFebruary 23, 2026 | tipranks.comMangoceuticals, Inc. Reports Promising Results for Antiviral Compound MGX-0024 in Poultry Respiratory Disease ManagementFebruary 23, 2026 | quiverquant.comQMangoceuticals' Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government StudyFebruary 23, 2026 | globenewswire.comMangoceuticals stock skyrockets 50% Friday: What's driving the rally?February 20, 2026 | msn.comMangoRx Experiences Initial Success with Newly Launched $99/month All-Inclusive Injectable Testosterone Replacement Therapy (TRT) Treatment ProgramFebruary 19, 2026 | globenewswire.comMangoceuticals Receives Nasdaq Notice on Minimum Bid PriceFebruary 6, 2026 | tipranks.comMangoceuticals (NASDAQ:MGRX) Stock Price Up 0.5% – Here’s WhyDecember 31, 2025 | defenseworld.netDNew MarketBeat Followers Over TimeMedia Sentiment Over TimeATIP, BMGL, MGRX, and ACON Company DescriptionsAclarion NASDAQ:ACON$3.28 +0.13 (+4.13%) Closing price 04:00 PM EasternExtended Trading$3.28 0.00 (-0.15%) As of 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.ATI Physical Therapy NYSE:ATIPATI Physical Therapy, Inc. operates as an outpatient physical therapy provider that specializes in outpatient rehabilitation and adjacent healthcare services in the United States. It offers a range of services to its patients, including physical therapy to treat spine, shoulder, knee, and neck injuries or pain; work injury rehabilitation services, work conditioning and work hardening; and hand therapy, aquatic therapy, functional capacity evaluation, sports medicine, and wellness programs. It also provides ATI worksite solutions comprising injury prevention programs, work-related injury assessment services, wellness offerings, and consultations for employers; proprietary electronic medical records (EMR) integration, caseload management, and continuing education in therapy treatments; and sports medicine, including on-site sports physical therapy, clinical evaluation and diagnosis, immediate and emergency care, nutrition programs, and concussion management services. The company offers outpatient physical therapy services under the ATI brand name. ATI Physical Therapy, Inc. was founded in 1996 and is based in Bolingbrook, Illinois.Basel Medical Group NASDAQ:BMGL$0.59 +0.01 (+1.56%) Closing price 04:00 PM EasternExtended Trading$0.59 0.00 (0.00%) As of 05:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Basel Medical Group Ltd. is an investment holding company, which engages in providing orthopedic surgeries, medical care, and diagnosis services. Its services include orthopedic surgeries, medical care, rehabilitative therapy, physiotherapy, non-surgical treatments, medical diagnosis, magnetic resonance imaging, general surgery, x-ray, lump removal, sports medicine, and total hip replacement. The company was founded by Man Hing Yip on August 10, 2023 and is headquartered in Singapore.Mangoceuticals NASDAQ:MGRX$0.43 -0.05 (-10.97%) Closing price 04:00 PM EasternExtended Trading$0.44 +0.01 (+2.09%) As of 05:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys Dollar Tree Keeps Winning After Family Dollar Divorce Salesforce Stock Finds Support as AI Momentum Builds Marvell’s Pullback May Be the Setup Bulls Were Waiting For Snowflake and the Snowballing Impact of its AI Flywheel China Deal Ignites Boeing's Financial Afterburners IREN Is Flipping the Switch from Bitcoin to AI Flight Path to Profits: American Airlines Bets on SpaceX Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
